Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Pasello

Showing results (41-50 of 167) with videos related to

Pageof 17
Sort By:
Frontiers in Oncology|May 2, 2022
SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet NeedsLorenzo Belluomini, Lorenzo Calvetti, Alessandro Inno, et al.
Anticancer Research|April 12, 2015
Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancerGiulia Pasello, Paolo Carli, Fabio Canova, et al.
Diagnostics (Basel, Switzerland)|August 14, 2025
RadiomiX for Radiomics Analysis: Automated Approaches to Overcome Challenges in ReplicabilityHarel Kotler, Luca Bergamin, Fabio Aiolli, et al.
The Oncologist|June 20, 2020
Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World ExperienceLaura Bonanno, Alberto Pavan, Alessandra Ferro, et al.
Lung Cancer (Amsterdam, Netherlands)|February 8, 2011
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experienceGiulia Pasello, Samuele Nicotra, Giuseppe Marulli, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|January 26, 2013
Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesotheliomaGiuseppe Marulli, Francesco Di Chiara, Fausto Braccioni, et al.
Journal of Medical Economics|April 27, 2026
Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in ItalyIlaria Valentini, Filippo Rumi, Eugenio Di Brino, et al.
Journal of Clinical Medicine|April 3, 2021
Relapse Patterns and Tailored Treatment Strategies for Malignant Pleural Mesothelioma Recurrence after Multimodality TherapyAlice Bellini, Andrea Dell'Amore, Stefano Terzi, et al.
Frontiers in Immunology|February 13, 2024
Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patientsMartina Lorenzi, Maria Vittoria Resi, Laura Bonanno, et al.
British Journal of Cancer|March 10, 2022
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?Laura Bonanno, Alessandro Dal Maso, Alberto Pavan, et al.
Pageof 17

Showing results (41-50 of 167) with videos related to

Sort By:
Pageof 17
Frontiers in Oncology|May 2, 2022
SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet NeedsLorenzo Belluomini, Lorenzo Calvetti, Alessandro Inno, et al.
Anticancer Research|April 12, 2015
Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancerGiulia Pasello, Paolo Carli, Fabio Canova, et al.
Diagnostics (Basel, Switzerland)|August 14, 2025
RadiomiX for Radiomics Analysis: Automated Approaches to Overcome Challenges in ReplicabilityHarel Kotler, Luca Bergamin, Fabio Aiolli, et al.
The Oncologist|June 20, 2020
Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World ExperienceLaura Bonanno, Alberto Pavan, Alessandra Ferro, et al.
Lung Cancer (Amsterdam, Netherlands)|February 8, 2011
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experienceGiulia Pasello, Samuele Nicotra, Giuseppe Marulli, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|January 26, 2013
Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesotheliomaGiuseppe Marulli, Francesco Di Chiara, Fausto Braccioni, et al.
Journal of Medical Economics|April 27, 2026
Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in ItalyIlaria Valentini, Filippo Rumi, Eugenio Di Brino, et al.
Journal of Clinical Medicine|April 3, 2021
Relapse Patterns and Tailored Treatment Strategies for Malignant Pleural Mesothelioma Recurrence after Multimodality TherapyAlice Bellini, Andrea Dell'Amore, Stefano Terzi, et al.
Frontiers in Immunology|February 13, 2024
Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patientsMartina Lorenzi, Maria Vittoria Resi, Laura Bonanno, et al.
British Journal of Cancer|March 10, 2022
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?Laura Bonanno, Alessandro Dal Maso, Alberto Pavan, et al.
Pageof 17